| Assessment Status | Rapid Review complete |
| HTA ID | 24016 |
| Drug | Dantrolene sodium hemiheptahydrate |
| Brand | Agilus® |
| Indication | In combination with adequate support measures, dantrolene sodium hemiheptahydrate is indicated for the treatment of malignant hyperthermia in adults and children of all ages. |
| Assessment Process | |
| Rapid review commissioned | 20/05/2024 |
| Rapid review completed | 27/06/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dantrolene sodium hemiheptahydrate (Agilus®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. February 2025
